Destiny Pharma – Neil Clark, CEO (AIM:DEST) One2One Virtual Forum 10th December 2021

Future Pharma PLC (Aim:DEST) (Future Pharma PLC (Aim:DEST)) is a medical phase, impressive biotechnology business concentrated on the enhancement of novel medications that can protect against life-threatening bacterial infections. The firm’s pipeline has novel microbiome-primarily based biotherapeutics and XF drug medical assets including NTCD-M3, a Section 3 completely ready treatment method for the avoidance of C. difficile infection (CDI) recurrence which is the top lead to of healthcare facility obtained bacterial infections in the US. Destiny’s pipeline also incorporates XF-73 nasal gel, which has recently completed a beneficial Section 2b medical demo targeting the avoidance of put up-surgical staphylococcal healthcare facility bacterial infections including MRSA. The business is also co-developing SPOR-COV, a novel, biotherapeutic products for the avoidance of COVID-19 and other viral respiratory bacterial infections.